Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adjuvanted influenza vaccine combined with CpG7909 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Subunit influenza vaccine | BIOLOGICAL | 0.5 mL single dose vaccine |
| Adjuvanted influenza vaccine | BIOLOGICAL | 0.5 mL single dose vaccine |
| Adjuvanted influenza vaccine combined with CpG7909 | BIOLOGICAL | 0.5 ml influenza vaccine combined with 10 mcg of CpG7909 |
| Adjuvanted influenza vaccine combine with CpG7909 | BIOLOGICAL | 0.5 mL single dose vaccine combined with 30 mcg of CpG7909 |
Inclusion Criteria: * Healthy subjects aged 18 to ≤40 years Exclusion Criteria: * Any serious disease, hypersensitivity to egg or vaccine components, neurological symptoms or positive antibody test against dsDNA, RF, ANA or thyroid. * Abnormal TSH from blood samples collected during the screening...
It is an investigational influenza vaccine developed by Novartis AG that combines a flu vaccine with the adjuvant CpG7909. It is designed to prevent influenza infection. The vaccine was studied in a Phase 1 clinical trial that has been completed.
It is being developed for the prevention of influenza infection. The vaccine is intended to stimulate an immune response against influenza virus. It has been tested in a Phase 1 trial in healthy adult volunteers.
The vaccine is developed by Novartis AG, which trades under the ticker NVS. Novartis conducted the clinical development of this adjuvanted influenza vaccine candidate.
The adjuvanted influenza vaccine combined with CpG7909 is in Phase 1 development. The Phase 1 trial has been completed. It is an investigational vaccine and has not been approved by the FDA.
The vaccine was studied in a single Phase 1 trial, NCT00559975, titled "Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine." The trial enrolled 60 participants in Switzerland and has been completed.